Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Conditions
Keywords
Acalabrutinib, Obinutuzumab, 20-503
Brief summary
This study will test the safety of limiting treatment time with acalabrutinib and obinutuzumab in people who have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The researchers want to find out whether stopping the study drugs when the cancer responds to the treatment, followed by a period of observation in which no treatment is given, is better than, the same as, or worse than the usual approach. A usual treatment for CLL and SLL is to give the study drugs continuously until the cancer progresses, even if the disease is in remission. But when people receive these drugs for long periods of time, they can have serious side effects and their cancer can become resistant to treatment.
Interventions
DRUGAcalabrutinib
Acalabrutinib for a minimum of 13 cycles and maximum 26 cycles.
DRUGObinutuzumab
Obinutuzumab will be administered during Cycles 2-7.
Sponsors
Memorial Sloan Kettering Cancer Center
AstraZeneca
Genentech, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This is a phase II, multicenter clinical trial.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Signed informed consent form (ICF). Legally Authorized Representatives are permitted. * Ability and willingness to comply with requirements of the study protocol * ≥ 18 years-old * Have documented previously untreated CLL or SLL per WHO criteria and require treatment per iwCLL guidelines * ECOG performance status of 0, 1, or 2, with no deterioration over the previous 2 weeks prior to baseline or day of first dosing * Participants must have adequate organ and marrow function as defined below: * Total bilirubin ≤ 1.5 times upper limit of normal (ULN), unless there is a disease involvement of the liver, hemolysis, or a known history of Gilbert's disease. * Hemoglobin ≥ 8 g/dL without transfusion support, unless anemia is due to marrow involvement of CLL. * Absolute neutrophil count (ANC) ≥ 1.0 x 10\^9/L. * AST and ALT ≤ 2.5 times the ULN. * Creatinine clearance (CrCl) \> 30 mL/min as calculated using modified Cockcroft- Gault or MDRD Formula * PT/INR ≤ 2 times the ULN and aPTT ≤ 2 times the ULN unless the elevation in PT/INR or aPTT is solely attributable to direct oral anticoagulant. * Platelet count without transfusion support must be ≥ 50,000 cells/mm3 or ≥ 30,000 cells/mm\^3 in subjects with documented bone marrow involvement, as determined locally. * For women of childbearing potential: Agreement to remain abstinent (refrain from heterosexual intercourse) or use a highly effective contraceptive method (failure rate of \< 1%) per year during the treatment period and for at least 18 months after the last dose of study medication. Women of childbearing potential must have a negative serum pregnancy test result within 3 days prior to initiation of study drug * Women must refrain from donating eggs during this same period * A woman is considered of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus) * Examples of contraceptive methods with a failure rate of \< 1 % per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices * Examples of contraceptive methods with a failure rate of \< 1 % per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices * With female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of \< 1% per year during the treatment period and for at least 6 months after- the last dose of obinutuzumab; men must refrain from donating sperm during this same period * With pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 6 months after the last dose of obinutuzumab to avoid exposing the embryo * The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient; periodic abstinence (e.g., calendar, ovulation, symptothermal, or post-ovulation methods) and withdrawal are not acceptable methods of contraception
Exclusion criteria
* Prior CLL-directed therapy °Excluding corticosteroid therapy started for non-CLL related reasons or brief courses for disease related symptom management * Received any investigational drug within 30 days or 5 half-lives (whichever is shorter) before first dose of study drug * History of prior malignancy that could affect compliance with the protocol or interpretation of results, except for the following: * Curatively treated basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or carcinoma in situ of the prostate at any time prior to study. * Other cancers not specified above that have been curatively treated by surgery and/or radiation therapy from which subject is disease-free for ≥3 years without further treatment. * Transformation of CLL to aggressive lymphoma (Richter's transformation to NHL or Hodgkin's lymphoma, or pro-lymphocytic leukemia) * CLL with deletion of chromosome 17p and/or TP53 mutation. Patients must have FISH or array CGH analysis and NGS for TP53 mutations locally as per SOC within 60 days of C1D1 (peripheral blood, bone marrow or lymph node with disease involvement are acceptable sources) as SOC. * History of or ongoing confirmed central nervous system (CNS) lymphoma. * Known hypersensitivity to any active ingredient in the study drugs. * Active bleeding, or presence of known bleeding disorder (e.g. von Willebrand's disease) or hemophilia. * Any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as: * Clinically significant cardiac disease that includes symptomatic arrhythmia (subjects with controlled, asymptomatic atrial fibrillation or other atrial arrhythmias during screening are allowed to enroll on study) * Intracranial hemorrhage, stroke within 6 months of study enrollment * Symptomatic, or history of documented congestive heart failure (NY Heart Symptomatic, or history of documented congestive heart failure (NY Heart Association functional classification III-IV * Myocardial infarction within 6 months of enrollment * Concomitant use of medication known to cause QT prolongation or torsade's de pointes should be used with caution and at investigator's discretion * Angina not well-controlled by medication * Poorly controlled or clinically significant atherosclerotic vascular disease including cerebrovascular accident (CVA), transient ischemic attack (TIA), angioplasty, cardiac/vascular stenting within 6 months of study enrollment * Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 2 weeks prior to cycle 1 day 1 including subjects with positive cytomegalovirus \[CMV\] DNA polymerase chain reaction \[PCR\]. * Requires the use of warfarin or equivalent Vitamin K antagonist * Requires or received the following agents within 7 days prior to the first dose of acalabrutinib-obinutuzumab combination therapy: * Patients who are positive for HCV antibody must be negative for HCV by polymerase chain reaction (PCR) to be eligible for study participation * Patients with occult or prior HBV infection (defined as positive total hepatitis B core antibody \[HBcAb\] and negative HBsAg) may be included if HBV DNA is undetectable by PCR. These patients must be willing to undergo sequential DNA testing as per institutional standards (every 1-3 months) and antiviral prophylaxis as per institutional standards. * Uncontrolled AIHA (autoimmune hemolytic anemia) or ITP (idiopathic thrombocytopenic purpura). * Presence of a gastrointestinal ulcer diagnosed by endoscopy within 3 months before screening, this is subject to investigator's discretion * Known infection with HIV (testing not required as part of screening) * Receipt of live-virus vaccines within 28 days prior to the initiation of study treatment * Pregnant or lactating, or intending to become pregnant during the study * Major surgical procedures within 28 days of first dose of study drug. Note: if a subject had major surgery, they must have recovered adequately from any toxicity and/or complications from the intervention before the first dose of study drug. * Malabsorption syndrome or other condition that precludes enteral route of administration; this is subject to investigator discretion * Has difficulty with or is unable to swallow oral medication * Concurrent participation in the treatment phase of an interventional clinical trial * Unwilling or unable to participate in all required study evaluations and procedures. Unable to provide a signed and dated informed consent form (ICF) and authorization to use protected health information (in accordance with national and local patient privacy regulations).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| progression-free survival (PFS) | 36 months | Progression free survival (PFS) will be measured from the time the patient initiates treatment, until documented progression of disease, relapse, or death due to any cause, whichever comes first. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse events from Acalabrutinib with Obinutuzumab | 3 years | Definitions found in the Common Terminology Criteria for Adverse Events version 5 (CTCAE v 5.0) will be used for grading the severity (intensity) of adverse events. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORMeghan Thompson, MD
Memorial Sloan Kettering Cancer Center
Outcome results
None listed